Johan J. Lombaard

Bloemfontein, FS, South Africa

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.

Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE Study.

Journal: The Pediatric infectious disease journal

Published: August 19, 2025

Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study.

Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-naïve Children With HIV ≥6 to <12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study.

Journal: The Pediatric infectious disease journal

Published: April 18, 2025

The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.

The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.

Journal: Southern African journal of HIV medicine

Published: February 05, 2025

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.

Journal: Human vaccines & immunotherapeutics

Published: December 12, 2024

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study.

Journal: PLOS global public health

Published: June 02, 2024

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.

Journal: The Lancet. Microbe

Published: August 17, 2023

Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.

Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.

Journal: Antiviral therapy

Published: April 29, 2022

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.

Journal: Antimicrobial agents and chemotherapy

Published: December 06, 2021

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

Journal: The lancet. HIV

Published: December 01, 2021

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.

Journal: The New England journal of medicine

Published: May 05, 2021

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.

Journal: AIDS and behavior

Published: May 25, 2020

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

Journal: The New England journal of medicine

Published: March 05, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026